Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | Tocilizumab: CAR-T cell therapy in DLBCL

Matthew Frigault • 18 Aug 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Tisagenlecleucel Tocilizumab
ELIANA

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, discusses the use of tocilizumab after CAR-T cell therapy for the treatment of cytokine release syndrome (CRS) in refractory diffuse large B-Cell lymphoma (DLBCL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Matthew Frigault

Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma
0:53
Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma
Matthew Frigault • 10 Dec 2023
Itacitinib for the prevention of immune effector cell therapy–associated CRS
0:58
Itacitinib for the prevention of immune effector cell therapy–associated CRS
Matthew Frigault • 12 Dec 2023
Prophylaxis and management of CRS & ICANS
Prophylaxis and management of CRS & ICANS
Matthew Frigault • 12 May 2023
Rapid CAR manufacture
Rapid CAR manufacture
Matthew Frigault • 12 May 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Matthew Frigault • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Matthew Frigault • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Matthew Frigault • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Matthew Frigault • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals